Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-BBz CAR T cells
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19-BBz CAR T cells are a second-generation chimeric antigen receptor (CAR) T-cell therapy designed to target the CD19 antigen, a protein expressed on the surface of most B-cell malignancies. The "BBz" designation refers to the intracellular signaling domains: the 4-1BB (CD137) costimulatory domain and the CD3ζ (zeta) activation domain. This specific architecture is characterized by enhanced T-cell persistence and a distinct metabolic profile compared to CD28-based CARs, making it a foundational design in cellular immunotherapy. It is the basis for several approved therapies, including tisagenlecleucel, and is widely used in clinical trials for B-cell acute lymphoblastic leukemia (B-ALL) and various B-cell lymphomas.
- Other names
- CD19-4-1BB-CD3zeta CAR T cellsCD-19-4-1BB-CD3zeta CAR T cellsCD 19-4-1BB-CD3zeta CAR T cellsanti-CD19-BBz CAR-Tanti-CD-19-BBz CAR-Tanti-CD 19-BBz CAR-Tsecond-generation CD19 CAR T cellsCD19-BBz CAR-TCD-19-BBz CAR-TCD 19-BBz CAR-T
02
Targets
Beyond the preview
Go deeper on CD19-BBz CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-BBz CAR T cells.